Thomson Reuters/Uni...
Health Care: Drugs
Merrimack Pharmaceuticals Inc (MACK: NASDAQ)
$5.52 0.04 | 0.73%
05/17/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:9.61
Price Earnings Comparisons:
| MACK | Sector Avg. | S&P 500 |
|---|---|---|
| 9.61 | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -15.17 | -25.10 | 0.00 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 43.00 | 0.00 | 0.00 |
| Net Income | 0.00 | 0.00 | |
| EPS | 0.00 | 0.00 |
Earnings for MACK:
| EBITDA | -89.00 |
| REVENUE | 48.92M |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.29 | $-0.28 | $-1.03 | $-1.03 |
| Number of Analysts | 4 | 3 | 4 | 4 |
| High Estimate | $-0.26 | $-0.26 | $-0.72 | $-0.52 |
| Low Estimate | $-0.31 | $-0.32 | $-1.21 | $-1.80 |
| Prior Year | $-0.22 | $-0.25 | $-1.28 | $-1.03 |
| Growth Rate (Year over Year) | -31.82% | -13.33% | 19.34% | 0.48% |
Portfolios with MACK
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks With Big Insider Buy...
- ProTPG-Axon Capital
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
Latest MACK Headlines from TheStreet
- Merrimack Pharmaceuticals Completes Enrollment Of One Cohort In Neoadjuvant Phase 2 Study Of MM-121 In HER2-Negative Breast Cancer 04.15.13 | 08:04 am
- Merrimack Pharmaceuticals Announces Webcast Of Inaugural Research & Development Day 04.05.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment In A Phase 2 Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers 03.18.13 | 08:03 am
- Merrimack Reports Fourth Quarter And Full Year 2012 Financial Results 03.14.13 | 08:03 am
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
- Merrimack Pharmaceuticals Announces Timing Of Fourth Quarter 2012 Investor Conference Call 02.27.13 | 09:02 am
- Merrimack To Present At The Cowen And Company 33rd Annual Health Care Conference 02.25.13 | 12:02 pm
- Merrimack To Participate In Pancreatic Cancer Panel At The 2013 BIO CEO & Investor Conference 02.07.13 | 12:02 pm
- Merrimack Pharmaceuticals To Present Preclinical Data On Bispecific Antibody MM-111 In ErbB2-Positive Gastric Cancers 01.23.13 | 08:01 am
- Merrimack Pharmaceuticals Initiates Cross-Tumor Study To Investigate Potential Predictive Response Markers For A Developmental Nanotherapeutic Chemotherapy 12.19.12 | 02:12 pm
Press Releases for MACK
- Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model - PR Newswire 04.10.13 | 09:04 am
- Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor - PR Newswire 04.04.13 | 08:04 am
- Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies - PR Newswire 04.02.13 | 09:04 am
- Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data For Novel Agent To Treat HER2-positive Breast Cancer And Preclinical Data On Companion Diagnostic - PR Newswire 12.10.12 | 09:12 am
- Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer - PR Newswire 11.27.12 | 09:11 am
- Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers - PR Newswire 10.02.12 | 08:10 am
- Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers - PR Newswire 09.18.12 | 11:09 am
- Merrimack Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering - PR Newswire 03.28.12 | 11:03 pm
Partner Headlines for MACK
- After Hours Most Active for Nov 16, 2012 : SFD, QQQ, WIN, TSN, MSFT, TSS, BAC, MYL, ZGNX, WM, MACK, MMC - NASDAQ 11.16.12 | 09:11 pm
- Morning Market Losers - Benzinga 09.25.12 | 09:09 am
- 5 Low-Debt Biotech Stocks Forecasted For Growth - Seeking Alpha 09.22.12 | 09:09 am
- Jim Cramer Watchdog: SELL Morgan Stanley and 'BUY, BUY, BUY' These 3 HOT Stocks - Wall St. Cheat Sheet 07.20.12 | 11:07 am
